Canaccord lowered the firm’s price target on Insulet (PODD) to $435 from $450 and keeps a Buy rating on the shares. The firm said the company capped off a strong 2025 with a Q4 beat as the US drove upside in the quarter and was driven by T2D adoption. Canaccord feels conviction in our thesis that Insulet is the company best positioned in the AID world, with the Omnipod having the best form factor for continued adoption in both the T1 and T2 populations, scalable to the pharmacy channel.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet: Strong Q4 Execution and Encouraging 2026 Outlook Offset by Valuation and Competitive Pressures, Justifying Hold Rating
- Insulet: Sustained Growth Runway and Underappreciated Long‑Term Upside Support Buy Rating
- Midday Fly By: Berkshire cuts Amazon stake, MSG Sports weighs spinoff
- Early notable gainers among liquid option names on February 18th
- Morning Movers: SolarEdge and Wingstop jump following quarterly results